NO932631L - Vaksine og fremgangsmaate mot sykdommer som skyldes patogene responser hos bestemte t-cellepopulasjoner - Google Patents

Vaksine og fremgangsmaate mot sykdommer som skyldes patogene responser hos bestemte t-cellepopulasjoner

Info

Publication number
NO932631L
NO932631L NO93932631A NO932631A NO932631L NO 932631 L NO932631 L NO 932631L NO 93932631 A NO93932631 A NO 93932631A NO 932631 A NO932631 A NO 932631A NO 932631 L NO932631 L NO 932631L
Authority
NO
Norway
Prior art keywords
cells
vaccine
vaccines
mediate
tcr
Prior art date
Application number
NO93932631A
Other languages
English (en)
Other versions
NO932631D0 (no
Inventor
Mark D Howell
Steven W Brostoff
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of NO932631D0 publication Critical patent/NO932631D0/no
Publication of NO932631L publication Critical patent/NO932631L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Vaksiner og en fremgangsmåte for vaksinering av et virveldyr for å for-hindre eller kontrollere bestemte T-celleformidlede sykdomstilstander, inkludert autoimmunsykdommer og den uregulerte replikasjon av T-celler. Vaksinen er sammensatt av en T-celle-reseptor (TCR) eller et fragment derav som svarer til en TCR som er til stede , på overflaten av T-celler som formidler sykdomstilstanden. Vaksinefragmentet kan være et peptid som svarer til sek-venser i TCR-er som er karakteristiske. > for T-cellene som formidler sykdomstilstanden. Et slikt peptid kan bindes til I vanlige antigener kompleksert tilHC-antigenpresenterende celler eller til. superantigener. Fremgangsmåte for be-stemmelse av passende aminosyresek-venser for slike vaksiner.aksinen 'i administreres til virveldyret på en måte som induserer en immunrespons i rettet mot TCR-en. til T-celler som formidler sykdomstilstanden. Denne immun-'i. responsen nedregulerer eller fjerner de. patogene T-cellene slik at sykdomspato-genesen fjernes. Spesifikke, variable p-kjedeområder i T-cellereseptorer, betegnet vp3, vp4, vpi2, vpi4 og vpi7,. som er forbundet med patogenesen til autoimmunsykdommer, slik som reumatoid artritt (RA) og multippel sklerose (MS). Fremgangsmåter for å påvise, for-hindre og behandle RA og MS. Fremgangsmåter for administrering av DNA eller. RNA som koder for polypeptidene som kan anvendes som vaksiner ifølge foreligg-ende oppfinnelse, i vevscellene til et individ.
NO93932631A 1991-01-22 1993-07-21 Vaksine og fremgangsmaate mot sykdommer som skyldes patogene responser hos bestemte t-cellepopulasjoner NO932631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64461191A 1991-01-22 1991-01-22
PCT/US1992/000482 WO1992012996A2 (en) 1991-01-22 1992-01-21 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Publications (2)

Publication Number Publication Date
NO932631D0 NO932631D0 (no) 1993-07-21
NO932631L true NO932631L (no) 1993-09-21

Family

ID=24585631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932631A NO932631L (no) 1991-01-22 1993-07-21 Vaksine og fremgangsmaate mot sykdommer som skyldes patogene responser hos bestemte t-cellepopulasjoner

Country Status (6)

Country Link
EP (2) EP0722738A3 (no)
JP (2) JPH06507384A (no)
AU (1) AU1271692A (no)
CA (1) CA2101065A1 (no)
NO (1) NO932631L (no)
WO (1) WO1992012996A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6464978B1 (en) * 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
ES2144418T3 (es) * 1991-05-31 2000-06-16 Connetics Corp Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
US5976789A (en) * 1991-07-17 1999-11-02 Bio Merieux System of probes enabling HLA-DR typing to be performed, and typing method using said probes
EP0623025A1 (en) * 1991-12-24 1994-11-09 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JPH08501554A (ja) * 1992-09-14 1996-02-20 ブリガム・アンド・ウイメンズ・ホスピタル 慢性関節リウマチの治療剤および治療方法
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
AU1812095A (en) * 1994-02-23 1995-09-11 Akzo Nobel N.V. A t cell receptor sequence specifically associated with an immune disease
GB9423085D0 (en) * 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
DK0998556T3 (da) * 1997-07-21 2005-10-17 Arpi Matossian-Rogers Diagnose og behandling af sygdomme ved anvendelse af anti- T-celle-receptor-Vbeta-antistoffer eller -peptider som genkendelse af antistofferne, og endokrint udskillelsesregulatorisk protein 1 (ESRP 1)
WO2000006733A2 (en) * 1998-07-29 2000-02-10 Heska Corporation T cell receptor proteins, nucleic acid molecules, and uses thereof
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20080051451A1 (en) * 2006-03-15 2008-02-28 Marcel Linschoten Autoimmune conditions and NADPH oxidase defects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
ES2062519T5 (es) * 1989-03-21 2003-07-16 Immune Response Corp Inc Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
AU652540B2 (en) * 1989-07-19 1994-09-01 Xoma Corporation T cell receptor peptides as therapeutics for autoimmune and malignant disease
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
JPH06507384A (ja) 1994-08-25
CA2101065A1 (en) 1992-07-23
EP0722738A3 (en) 1996-10-23
EP0568623A1 (en) 1993-11-10
WO1992012996A2 (en) 1992-08-06
AU694062B2 (en) 1998-07-09
JP2001097886A (ja) 2001-04-10
WO1992012996A3 (en) 1992-12-10
AU1271692A (en) 1992-08-27
EP0722738A2 (en) 1996-07-24
NO932631D0 (no) 1993-07-21
AU7032796A (en) 1997-01-16

Similar Documents

Publication Publication Date Title
NO932631L (no) Vaksine og fremgangsmaate mot sykdommer som skyldes patogene responser hos bestemte t-cellepopulasjoner
Willenborg et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis.
Lehmann et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
Okuda et al. Genetic Control of Immune Response to Sperm Whale Myoglobin in Mice: II. T Lymphocyte Proliferative Response to the Synthetic Antigenic Sites
Bonneville et al. Intestinal intraepithelial lymphocytes are a distinct set of γδ T cells
Schwimmbeck et al. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus.
Tanaka et al. A pivotal role of IL-12 in Th1-dependent mouse liver injury
Rajasekar et al. Self heat shock and gamma delta T-cell reactivity.
Sundar et al. Human immunodeficiency virus glycoprotein (gp120) infused into rat brain induces interleukin 1 to elevate pituitary-adrenal activity and decrease peripheral cellular immune responses.
Liu et al. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid.
Goetzl et al. Neuroimmunology
Gozes et al. Activity-dependent neurotrophic factor (ADNF) An extracellular neuroprotective chaperonin?
KR920700674A (ko) 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법
US20080089900A1 (en) Identification of self and non-self antigens implicated in autoimmune disease
WO1993012814A3 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
Erhan et al. Do immunoglobulins have proteolytic activity?
Henderson et al. A peptide inhibitor of human immunodeficiency virus infection binds to novel human cell surface polypeptides
Bockova et al. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies
Yamamoto et al. Antigenicity of mouse interferons: distinct antigenicity of the two L cell interferon species
Ablamunits et al. Islet T cells secreting IFN-γ in NOD mouse diabetes: arrest by p277 peptide treatment
CN101330928A (zh) 用于预防和治疗丙型肝炎的免疫刺激剂组合
Cockfield et al. Regulation of IFN-gamma and tumor necrosis factor-alpha expression in vivo. Effects of cycloheximide and cyclosporine in normal and lipopolysaccharide-treated mice.
JPH05500653A (ja) リウマチ様関節炎の処置法
ES2144418T3 (es) Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
CHUN et al. Constitutive and regulated expression of the class Ib molecule Qa‐1 in pancreatic β cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application